Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status  Phase of research How it helps Latest publication
Naphthazarin
Potential treatment - pre-clinical evidence Natural product Antiviral Apr/24/2021
N-[(2S)-1-[[(3S)-1-(benzenesulfonyl)-5-phenylpentan-3-yl]amino]-1-oxo-3-phenylpropan-2-yl]-4-methylpiperazine-1-carboxamide
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/31/2021
Glycyrrhizic acid
Potential treatment - pre-clinical evidence Natural product Antiviral Apr/02/2021
mAb 58
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/04/2022
PF-00835231
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/26/2022
Menadione
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Apr/24/2021
Niclosamide
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Apr/07/2021
rLVS ΔcapB/SCoV2 MN
Potential treatment - pre-clinical evidence Experimental Vaccine Mar/30/2021
COV2-2489
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/16/2021
Nb11‐59
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/04/2021
Salvianolic acid C
Potential treatment - pre-clinical evidence Natural product Antiviral Feb/08/2021
COV2-2676
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/16/2021
12f
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/08/2021
Ambroxol
Potential treatment - pre-clinical evidence Natural product Other treatment Apr/22/2021
mAb 4A8
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/12/2021
Bepridil
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Feb/17/2021
(Recombinant) IL-3
Potential treatment - pre-clinical evidence Experimental Other treatment Feb/18/2021
[SARSHRC-PEG4]2-chol
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/17/2021
MI-09
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/18/2021
MI-30
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/18/2021